Suscribirse

Seroprevalence and seroconversion for tick-borne diseases in a high-risk population in the northeast United States - 08/09/11

Doi : 10.1016/S0002-9343(99)00046-7 
Eileen Hilton, MD a, , James DeVoti, PhD a, Jorge L Benach, PhD b, Maria L Halluska, MD b, Dennis J White, PhD b, Helen Paxton, MS c : MT, J.Steven Dumler, MD d
a North Shore–Long Island Jewish Health System, Division of Clinical Research, The Long Island Campus for the Albert Einstein College of Medicine, New Hyde Park, New York, USA 
b The State of New York Department of Health and Department of Pathology, State University of New York at Stony Brook, Stony Brook, New York, USA 
c Integrated Diagnostics, Inc, Baltimore, Maryland, USA 
d Department of Pathology, The Johns Hopkins Medical Institution, Baltimore, Maryland, USA 

*Requests for reprints should be addressed to Eileen Hilton, MD, Long Island Jewish Medical Center, New Hyde Park, New York 11042

Abstract

PURPOSE: To determine the prevalence of serologic reactivity, the 1-year incidence of seroconversion, and the frequency of multiple infections, and their associations with symptoms in a group of volunteers at high risk for tick-borne infections in New York state.

METHODS: We performed a seroepidemiologic study of Lyme borreliosis, 2 of the ehrlichioses, Rocky Mountain spotted fever, and babesiosis among 671 participants who lived or worked in a high-risk area (mainly in eastern Long Island, New York) for tick-borne diseases. Sera were collected in the winters of 1994 and 1995. Signs and symptoms of tick-borne disease were monitored monthly by mail and telephone. Lyme borreliosis serologies were done by enzyme-linked immunosorbent assay and Western blot. Rocky Mountain spotted fever serologies were initially screened using Dip-S-Ticks, followed by specific indirect immunofluorescence. Ehrlichiosis serologies were determined by epifluorescent microscopy, as were antibodies to Babesia microti.

RESULTS: Of the 671 participants, 88 (13%) had antibodies to ≥1 tick-borne organisms, including 34 (5% of the total) with antibodies to Borrelia burgdorferi.Twenty-seven participants had evidence of exposure to B. burgdorferiat baseline. Seven participants (1%) seroconverted during the course of the study, 5 of whom were symptomatic for Lyme borreliosis. Antibodies to spotted fever group rickettsiae were seen in 28 participants (4%), 22 of whom were positive at baseline and 6 of whom seroconverted during the observation period. None of the seropositive patients had any symptoms or signs of infection. Twenty-four participants (3%) had serologic evidence of exposure to Ehrlichia (all but one to Ehrlichia equi); 5 (0.7%) seroconverted during the observation period, including 3 subjects who were asymptomatic. Antibodies to B. microti were seen in 7 participants (1%), including one asymptomatic seroconversion during the year of observation. There was evidence of possible dual infection in 5 patients.

CONCLUSION: In a high-risk population, there was evidence of exposure to 5 tick-borne pathogens; however, many infections were asymptomatic, and coinfections were rare.

El texto completo de este artículo está disponible en PDF.

Esquema


 Supported by the Helen and Irving P. Schneider Family and Connaught Laboratories.


© 1999  Excerpta Medica Inc. Reservados todos los derechos.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 106 - N° 4

P. 404-409 - avril 1999 Regresar al número
Artículo precedente Artículo precedente
  • Hyponatremia: evaluating the correction factor for hyperglycemia
  • Teresa A. Hillier, Robert D. Abbott, Eugene J. Barrett
| Artículo siguiente Artículo siguiente
  • Effects of randomized assignment to a smoking cessation intervention and changes in smoking habits on respiratory symptoms in smokers with early chronic obstructive pulmonary disease: the lung health study
  • Richard E Kanner, John E Connett, David E Williams, A.Sonia Buist, for the Lung Health Study Research Group

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

@@150455@@ Voir plus

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2026 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.